Drugs / Cellgram-DC-PC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04615845 | Jun 2021 → Feb 2022 | castration-resistant prostate carcinoma | Pharmicell Co., Ltd. | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cellgram-DC-PC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04615845 ↗ |
| Modality | Cell therapy | “autologous dendritic cell anticancer immune cell therapy” NCT04615845 ↗ |
| Route | Subcutaneous | “injected subcutaneously near the inguinal lymph nodes” NCT04615845 ↗ |